

ESPI Current Report

Number: 10/2025
Date of preparation 17.02.2025
Company Genomtec SA based in Wrocław

Title	Conclusion of an agreement with an international consulting company
--------------	--

Legal basis: Article 17 section 1 of MAR - confidential information

Report Content: In reference to current report no. 29/2024, which provided information on, among other things, strategic directions of development, the Management Board of Genomtec S.A. with its registered office in Wrocław ("Genomtec", "Company") hereby informs that on February 17, 2025, the Company concluded an advisory agreement with an international consulting company with its registered office in Shanghai ("Partner") for the benefit of the Company, according to which the Partner will be responsible for the sale of, among others, the OncoSNAAT project in order to offer it to the market as soon as possible.

Recent months have shown that not only the Genomtec ID project has market potential, but also the OncoSNAAT project. In the opinion of the Management Board, there is a probability of selling two technologies to two different entities. This will require the involvement of greater resources, but on the other hand, in the opinion of the Management Board, it will potentially increase the value of the Company.

Under the concluded agreement, the Partner will provide advisory services to the Company, in particular in the area of establishing business contacts with potential strategic and financial investors or other entities that may be interested in conducting a financial transaction, M&A transaction or other business transaction with the Company. The result of the Partner's advisory services may be, in particular, a direct or indirect investment in the Company, including a joint venture, a license agreement or a product sales or marketing distribution agreement or the creation of a new company that will hold certain intellectual property rights of Genomtec.

The Partner's remuneration for the provision of advisory services includes an advance payment for the Partner's expenses and work and a part of the so-called success fee, depending on the result, i.e. the value of the transaction carried out.

The Agreement was concluded for a period of 10 months from the date of its signing by the parties, and its remaining provisions do not differ from the provisions commonly used in this type of agreements.

The Parties also agreed that the Partner will primarily focus on commercializing the technology related to the OncoSNAAT solution.

The Company will inform about subsequent significant stages related to the implementation of the above-mentioned agreement in appropriate reports.



Signatures of persons representing the Company:

Michał Wachowski - Member of the Management Board